Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Peptic Ulcer

Free Subscription Articles published in Aliment Pharmacol Ther Retrieve available abstracts of 80 articles: HTML format

Single Articles

July 2022
1. YEOMANS ND
   Editorial: risk of gastric and duodenal ulcers among new users of low-dose aspirin.
   Aliment Pharmacol Ther. 2022;56:334-335.
   PubMed    
   
   
   
2. RADADIYA D, Devani K, Rockey DC
   Editorial: the impact of red blood cell transfusion on inpatient mortality in upper gastrointestinal bleeding-authors' reply.
   Aliment Pharmacol Ther. 2022;56:338-339.
   PubMed    
   
   
   
3. ORPEN-PALMER J, Stanley AJ
   Editorial: the impact of red blood cell transfusion on inpatient mortality in upper gastrointestinal bleeding.
   Aliment Pharmacol Ther. 2022;56:336-337.
   PubMed    
   
   
   June 2022
4. ANG D, Koo SH, Chan YH, Tan TY, et al
   Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.
   Aliment Pharmacol Ther. 2022 Jun 3. doi: 10.1111/apt.17070.
   PubMed     Abstract available
   
   
   
5. PAUWELS A, Raymenants K, Geeraerts A, Boecxstaens V, et al
   Clinical trial: a controlled trial of baclofen add-on therapy in PPI-refractory gastro-oesophageal reflux symptoms.
   Aliment Pharmacol Ther. 2022 Jun 3. doi: 10.1111/apt.17068.
   PubMed     Abstract available
   
   
   
6. SONNENBERG A
   Letter: birth cohort pattern of Helicobacter pylori infection rates.
   Aliment Pharmacol Ther. 2022;55:1461.
   PubMed    
   
   
   
7. CHEN S, Liu D, Chen H, Liao A, et al
   The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study.
   Aliment Pharmacol Ther. 2022;55:1524-1533.
   PubMed     Abstract available
   
   
   May 2022
8. NGUYEN TNM, Sha S, Chen LJ, Holleczek B, et al
   Strongly increased risk of gastric and duodenal ulcers among new users of low-dose aspirin: Results from two large cohorts with new-user design.
   Aliment Pharmacol Ther. 2022 May 27. doi: 10.1111/apt.17050.
   PubMed     Abstract available
   
   
   February 2022
9. JIANG F, Guo CG, Leung WK
   Letter: the hidden reasons of long-term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication-authors' reply.
   Aliment Pharmacol Ther. 2022;55:374-375.
   PubMed    
   
   
   
10. YANG H, Hu B
    Letter: the hidden reasons of long-term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication.
    Aliment Pharmacol Ther. 2022;55:372-373.
    PubMed    
    
    
    January 2022
11. ZHENG X, Li N, Zhao J
    Letter: proton pump inhibitors and risk of myocardial infarction.
    Aliment Pharmacol Ther. 2022;55:139-140.
    PubMed    
    
    
    
12. NOLDE M, Ahn N, Dreischulte T, Ruckert-Eheberg IM, et al
    Letter: proton pump inhibitors and risk of myocardial infarction-authors' reply.
    Aliment Pharmacol Ther. 2022;55:141-142.
    PubMed    
    
    
    
13. YANG JC, Kao JY
    Treatment considerations in Helicobacter pylori management.
    Aliment Pharmacol Ther. 2022;55 Suppl 1:S22-S28.
    PubMed    
    
    
    
14. DORE MP, Graham DY
    Modern approach to the diagnosis of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2022;55 Suppl 1:S14-S21.
    PubMed    
    
    
    
15. SONNENBERG A
    Epidemiology of Helicobacter pylori.
    Aliment Pharmacol Ther. 2022;55 Suppl 1:S1-S13.
    PubMed     Abstract available
    
    
    November 2021
16. SUGANO K, Howden CW
    Editorial: the never-ending story-Helicobacter pylori and peptic ulcer disease.
    Aliment Pharmacol Ther. 2021;54:1350-1351.
    PubMed    
    
    
    
17. JIANG F, Guo CG, Leung WK
    Editorial: the never-ending story-Helicobacter pylori and peptic ulcer disease. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:1352-1353.
    PubMed    
    
    
    October 2021
18. SCHUITENMAKER JM, Oude Nijhuis RAB, Bredenoord AJ
    Letter: is wireless oesophageal pH monitoring the best technique to evaluate night-time reflux? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:976.
    PubMed    
    
    
    
19. RIBOLSI M, Savarino E
    Letter: is wireless oesophageal pH monitoring the best technique to evaluate night-time reflux?
    Aliment Pharmacol Ther. 2021;54:974-975.
    PubMed    
    
    
    September 2021
20. JIANG F, Guo CG, Cheung KS, Leung WK, et al
    Long-term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication: a population-based cohort study.
    Aliment Pharmacol Ther. 2021 Sep 16. doi: 10.1111/apt.16604.
    PubMed     Abstract available
    
    
    
21. NOLDE M, Ahn N, Dreischulte T, Ruckert-Eheberg IM, et al
    The long-term risk for myocardial infarction or stroke after proton pump inhibitor therapy (2008-2018).
    Aliment Pharmacol Ther. 2021 Sep 3. doi: 10.1111/apt.16565.
    PubMed     Abstract available
    
    
    
22. BASNAYAKE C, Geeraerts A, Pauwels A, Koek G, et al
    Systematic review: duodenogastroesophageal (biliary) reflux prevalence, symptoms, oesophageal lesions and treatment.
    Aliment Pharmacol Ther. 2021;54:755-778.
    PubMed     Abstract available
    
    
    August 2021
23. ZAMANI M, Alizadeh-Tabari S, Hasanpour AH, Eusebi LH, et al
    Systematic review with meta-analysis: association of Helicobacter pylori infection with gastro-oesophageal reflux and its complications.
    Aliment Pharmacol Ther. 2021 Aug 26. doi: 10.1111/apt.16585.
    PubMed     Abstract available
    
    
    
24. ARAI J, Aoki T, Hayakawa Y, Niikura R, et al
    Letter: predictive model for gastric cancer after eradication of Helicobacter pylori-a survival analysis using a deep learning algorithm.
    Aliment Pharmacol Ther. 2021;54:528-529.
    PubMed    
    
    
    
25. LIU Y, Chen M
    Letter: association between the risk of microscopic colitis and use of proton pump inhibitors.
    Aliment Pharmacol Ther. 2021;54:526-527.
    PubMed    
    
    
    
26. CHEN L, Glance S, Garg M
    Letter: response of eosinophilic oesophagitis to proton pump inhibitor therapy-the importance of biopsies at index endoscopy.
    Aliment Pharmacol Ther. 2021;54:521-522.
    PubMed    
    
    
    
27. LUI TKL, Leung WK
    Letter: predictive model for gastric cancer after eradication of Helicobacter pylori-a survival analysis using a deep learning algorithm. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:530-531.
    PubMed    
    
    
    
28. KATZ P
    Editorial: non-erosive reflux disease is often not GERD-time to change the definition or abandon the term?
    Aliment Pharmacol Ther. 2021;54:493-494.
    PubMed    
    
    
    July 2021
29. KIM YD, Wang J, Shibli F, Poels KE, et al
    No association between chronic use of ranitidine, compared with omeprazole or famotidine, and gastrointestinal malignancies.
    Aliment Pharmacol Ther. 2021 Jul 12. doi: 10.1111/apt.16464.
    PubMed     Abstract available
    
    
    
30. ROGERS BD, Gyawali CP
    Editorial: post-reflux swallow-induced peristaltic wave in eosinophilic oesophagitis-more questions than answers?
    Aliment Pharmacol Ther. 2021;54:188-189.
    PubMed    
    
    
    
31. FRAZZONI M, Frazzoni L, de Bortoli N, Savarino E, et al
    Editorial: post-reflux swallow-induced peristaltic wave in eosinophilic oesophagitis-more questions than answers? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:190-191.
    PubMed    
    
    
    
32. OUDE NIJHUIS RAB, Sweis R, Abdul-Razakq H, Schuitenmaker JM, et al
    Characterisation of patients with supine nighttime reflux: observations made with prolonged wireless oesophageal pH monitoring.
    Aliment Pharmacol Ther. 2021;54:144-152.
    PubMed     Abstract available
    
    
    June 2021
33. RIBOLSI M, Frazzoni M, Marabotto E, De Carlo G, et al
    Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus.
    Aliment Pharmacol Ther. 2021 Jun 28. doi: 10.1111/apt.16481.
    PubMed     Abstract available
    
    
    
34. SALVO EM, Ferko NC, Cash SB, Gonzalez A, et al
    Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors.
    Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16407.
    PubMed     Abstract available
    
    
    
35. YADAV Y, Talley NJ
    Editorial: microscopic colitis linked to NSAIDs but not proton pump inhibitors.
    Aliment Pharmacol Ther. 2021;53:1324-1325.
    PubMed    
    
    
    April 2021
36. FRAZZONI M, Frazzoni L, De Bortoli N, Russo S, et al
    Response of eosinophilic oesophagitis to proton pump inhibitors is associated with impedance-pH parameters implying anti-reflux mechanism of action.
    Aliment Pharmacol Ther. 2021 Apr 15. doi: 10.1111/apt.16371.
    PubMed     Abstract available
    
    
    March 2021
37. EUSEBI LH, Telese A, Cirota GG, Haidry R, et al
    Systmatic review with meta-analysis: Risk factors for Barrett's oesophagus in individuals with gastro-oesophageal reflux symptoms.
    Aliment Pharmacol Ther. 2021 Mar 11. doi: 10.1111/apt.16321.
    PubMed     Abstract available
    
    
    
38. HUSSAIN N, Shung DL
    Editorial: vitamin K antagonists versus direct oral anticoagulants in upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2021;53:751-752.
    PubMed    
    
    
    
39. LABENZ C, Schattenberg JM
    Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:673.
    PubMed    
    
    
    
40. SUGIYAMA T
    Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view.
    Aliment Pharmacol Ther. 2021;53:671-672.
    PubMed    
    
    
    
41. ROCCO A, Compare D, Sgamato C, Coccoli P, et al
    Editorial: proton pump inhibitor use in cirrhosis-a piece of the puzzle. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:665-666.
    PubMed    
    
    
    
42. CELSA C, Camma C
    Editorial: proton pump inhibitor use in cirrhosis-a piece of the puzzle.
    Aliment Pharmacol Ther. 2021;53:663-664.
    PubMed    
    
    
    February 2021
43. ABDEL-AZIZ Y, Metz DC, Howden CW
    Review article: potassium-competitive acid blockers for the treatment of acid-related disorders.
    Aliment Pharmacol Ther. 2021 Feb 16. doi: 10.1111/apt.16295.
    PubMed     Abstract available
    
    
    January 2021
44. LEUNG WK, Cheung KS, Li B, Law SYK, et al
    Applications of machine learning models in the prediction of gastric cancer risk in patients after Helicobacter pylori eradication.
    Aliment Pharmacol Ther. 2021 Jan 24. doi: 10.1111/apt.16272.
    PubMed     Abstract available
    
    
    
45. GOURIOU C, Bouguen G, Lahmek P, Pelaquier A, et al
    Outcomes of upper gastrointestinal bleeding are similar between direct oral anticoagulants and vitamin K antagonists.
    Aliment Pharmacol Ther. 2021 Jan 5. doi: 10.1111/apt.16236.
    PubMed     Abstract available
    
    
    December 2020
46. ROCCO A, Compare D, Sgamato C, Coccoli P, et al
    Impact of proton pump inhibitors on cytochrome P450 activity assessed by (13) C-aminopyrine breath test in patients with cirrhosis.
    Aliment Pharmacol Ther. 2020 Dec 28. doi: 10.1111/apt.16239.
    PubMed     Abstract available
    
    
    November 2020
47. CHAUDHARY S, Mackay D, Pell JP, Morris J, et al
    Upper gastrointestinal bleeding in Scotland 2000-2015: trends in demographics, aetiology and outcomes.
    Aliment Pharmacol Ther. 2020 Nov 18. doi: 10.1111/apt.16170.
    PubMed     Abstract available
    
    
    September 2020
48. VERMORKEN AJM, Zhu J, Cui Y
    Letter: does Helicobacter pylori infection limit the health effects of the Mediterranean diet?
    Aliment Pharmacol Ther. 2020;52:935-936.
    PubMed    
    
    
    
49. LEE PL, Suk FM, Kang YN
    Letter: does tranexamic acid reduce the need for surgery in patients with upper gastrointestinal bleeding?
    Aliment Pharmacol Ther. 2020;52:1088-1089.
    PubMed    
    
    
    
50. MARCUS EA, Pisegna JR
    Editorial: tegoprazan-the newest advance in the management of acid-related diseases.
    Aliment Pharmacol Ther. 2020;52:1074-1075.
    PubMed    
    
    
    August 2020
51. MEI LI C, Brusselaers N
    Letter: safety of proton pump inhibitors during pregnancy-authors' reply.
    Aliment Pharmacol Ther. 2020;52:740-741.
    PubMed    
    
    
    
52. ACAR S, Keskin-Arslan E, Uysal N, Karadas B, et al
    Letter: safety of proton pump inhibitors during pregnancy.
    Aliment Pharmacol Ther. 2020;52:739.
    PubMed    
    
    
    July 2020
53. LABENZ C, Worns MA, Adarkwah CC, Galle PR, et al
    Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study.
    Aliment Pharmacol Ther. 2020 Jul 30. doi: 10.1111/apt.16008.
    PubMed     Abstract available
    
    
    
54. CHO YK, Choi MG, Choi SC, Lee KM, et al
    Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer.
    Aliment Pharmacol Ther. 2020 Jul 23. doi: 10.1111/apt.15865.
    PubMed     Abstract available
    
    
    
55. LASERNA-MENDIETA EJ, Casabona S, Guagnozzi D, Savarino E, et al
    Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry.
    Aliment Pharmacol Ther. 2020 Jul 17. doi: 10.1111/apt.15957.
    PubMed     Abstract available
    
    
    
56. SCHNOLL-SUSSMAN F, Katz PO
    Letter: bone fracture risk among older long-term users of proton pump inhibitors. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:408.
    PubMed    
    
    
    
57. SUGIYAMA T
    Letter: bone fracture risk among older long-term users of proton pump inhibitors.
    Aliment Pharmacol Ther. 2020;52:407-408.
    PubMed    
    
    
    
58. MA ZF, Deraman MA, Coyle C, Lee YY, et al
    Editorial: simultaneous, prolonged monitoring of the acid pocket and oesophageal reflux. Authors' reply.
    Aliment Pharmacol Ther. 2020;52:398-399.
    PubMed    
    
    
    
59. KATZ PO, Castell DO
    Editorial: simultaneous prolonged monitoring of the acid pocket and oesophageal reflux.
    Aliment Pharmacol Ther. 2020;52:397-398.
    PubMed    
    
    
    June 2020
60. YUAN J, Zhang C, Sparks JA, Malspeis S, et al
    Regular use of proton pump inhibitor and risk of rheumatoid arthritis in women: a prospective cohort study.
    Aliment Pharmacol Ther. 2020 Jun 29. doi: 10.1111/apt.15834.
    PubMed     Abstract available
    
    
    
61. PAPAEFTHYMIOU A, Doulberis M, Polyzos SA, Katsinelos P, et al
    Letter: Helicobacter pylori infection and its role in oesophageal adenocarcinoma.
    Aliment Pharmacol Ther. 2020;51:1215-1216.
    PubMed    
    
    
    
62. GANTUYA B, El-Serag HB, Yamaoka Y
    Letter: are microbes other than Helicobacter pylori associated with gastric cancer? Authors' reply.
    Aliment Pharmacol Ther. 2020;51:1447-1449.
    PubMed    
    
    
    
63. HE C, Peng C, Xia Z, Lu N, et al
    Letter: are microbes other than Helicobacter pylori associated with gastric cancer?
    Aliment Pharmacol Ther. 2020;51:1446-1447.
    PubMed    
    
    
    
64. SUN Y
    Letter: Helicobacter pylori eradication treatment and the risk of oesophageal adenocarcinoma.
    Aliment Pharmacol Ther. 2020;51:1452-1453.
    PubMed    
    
    
    May 2020
65. TWUM-BARIMAH E, Abdelgadir I, Gordon M, Akobeng AK, et al
    Systematic review with meta-analysis: the efficacy of tranexamic acid in upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2020 May 3. doi: 10.1111/apt.15761.
    PubMed     Abstract available
    
    
    
66. ZHANG C, Li N, An Y
    Letter: the relationship between Helicobacter pylori and coronary heart disease.
    Aliment Pharmacol Ther. 2020;51:999.
    PubMed    
    
    
    March 2020
67. KUMAR S, Metz DC, Ginsberg GG, Kaplan DE, et al
    Oesophageal and proximal gastric adenocarcinomas are rare after detection of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2020 Mar 4. doi: 10.1111/apt.15677.
    PubMed     Abstract available
    
    
    January 2020
68. MACKE L, Schulz C, Koletzko L, Malfertheiner P, et al
    Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract-evidence from next-generation sequencing studies.
    Aliment Pharmacol Ther. 2020 Jan 28. doi: 10.1111/apt.15604.
    PubMed     Abstract available
    
    
    
69. LI CM, Zhernakova A, Engstrand L, Wijmenga C, et al
    Systematic review with meta-analysis: the risks of proton pump inhibitors during pregnancy.
    Aliment Pharmacol Ther. 2020 Jan 7. doi: 10.1111/apt.15610.
    PubMed     Abstract available
    
    
    
70. MCPHERSON SJ, Hammond CJ
    Letter: the Shock Index and predicting outcomes in patients with upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2020;51:311-312.
    PubMed    
    
    
    
71. BARDOU M, Barkun AN
    Editorial: how can we best promote the routine use of scores that are accurate at predicting outcomes in patients with upper gastrointestinal bleeding?
    Aliment Pharmacol Ther. 2020;51:305-306.
    PubMed    
    
    
    
72. PAPAEFTHYMIOU A, Doulberis M, Polyzos SA, Katsinelos P, et al
    Letter: Helicobacter pylori in proton pump inhibitor-associated biliary disease.
    Aliment Pharmacol Ther. 2020;51:313-314.
    PubMed    
    
    
    
73. STANLEY A
    Letter: the Shock Index and predicting outcomes in patients with upper gastrointestinal bleeding. Author's reply.
    Aliment Pharmacol Ther. 2020;51:312-313.
    PubMed    
    
    
    
74. KURLANDER JE, Rubenstein JH
    Editorial: moving towards the appropriate use of proton pump inhibitors.
    Aliment Pharmacol Ther. 2020;51:175-176.
    PubMed    
    
    
    
75. SCHNOLL-SUSSMAN F, Katz PO
    Editorial: moving towards appropriate use of proton pump inhibitors. Authors' reply.
    Aliment Pharmacol Ther. 2020;51:177.
    PubMed    
    
    
    
76. SCHEIMAN JM
    Commentary: cardioprotective aspirin and gastroduodenal ulcers.
    Aliment Pharmacol Ther. 2020;51:203.
    PubMed    
    
    
    October 2019
77. GHOSH G, Schnoll-Sussman F, Mathews S, Katz PO, et al
    Reported proton pump inhibitor side effects: what are physician and patient perspectives and behaviour patterns?
    Aliment Pharmacol Ther. 2019 Oct 30. doi: 10.1111/apt.15522.
    PubMed     Abstract available
    
    
    
78. SAFFOURI E, Blackwell C, Laursen SB, Laine L, et al
    The Shock Index is not accurate at predicting outcomes in patients with upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2019 Oct 23. doi: 10.1111/apt.15541.
    PubMed     Abstract available
    
    
    
79. GUO CG, Cheung KS, Zhang F, Chan EW, et al
    Risks of hospitalization for upper gastrointestinal bleeding in selective serotonin reuptake inhibitors users after Helicobacter pylori eradication therapy: a propensity score matching analysis.
    Aliment Pharmacol Ther. 2019 Oct 3. doi: 10.1111/apt.15507.
    PubMed     Abstract available
    
    
    April 2019
80. WONG GL, Ma AJ, Deng H, Ching JY, et al
    Machine learning model to predict recurrent ulcer bleeding in patients with history of idiopathic gastroduodenal ulcer bleeding.
    Aliment Pharmacol Ther. 2019;49:912-918.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Peptic Ulcer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: